Priority medicines for MPP licensing
Focusing efforts on key health products to achieve the greatest public health impact in LMICs
MPP Prioritisation Report 2025
The mission of the Medicines Patent Pool (MPP) is to facilitate the development of- and increase access to, life-saving medicines and health technologies for low- and middle-income countries (LMICs) through public-health oriented voluntary licensing and technology transfer. To do so, the first step for MPP is to identify suitable candidates using a prioritisation framework that is applied to assess products of potential interest in all health areas.
MPP’s list of priority and watchlist products is regularly updated, by following a peer-reviewed prioritisation framework. It outlines the health areas on which MPP focuses its activities.
MPP’s prioritisation list includes medicines and health technologies for which expanded access in LMICs could provide significant health benefits over standards of care, and where a voluntary agreement, including licensing and/or technology transfer, through MPP could lead to substantial public health impact.
This prioritisation process contributes to ensuring MPP focuses its efforts on medicines for which licensing could have the greatest public health impact. By using a robust framework, MPP evaluates product candidates and publishes a list of prioritised and watchlist medicines and health innovations in a range of health areas, for which a potential MPP intervention may support increased access.
It should be noted that MPP does not include in its prioritisation list the medicines and health innovations for which it has already signed agreements. The list of MPP previously signed agreements to enable access are available on the “agreements with innovators” section of MPP’s website.